key: cord-0931434-b7slt9rg
authors: Li, Mingxi; Ren, Yifei; Aw, Zhen Qin; Chen, Bo; Yang, Ziqing; Lei, Yuqing; Cheng, Lin; Liang, Qingtai; Hong, Junxian; Yang, Yiling; Chen, Jing; Wong, Yi Hao; Shan, Sisi; Zhang, Senyan; Ge, Jiwan; Wang, Ruoke; Shi, Xuanling; Zhang, Qi; Zhang, Zheng; Chu, Justin Jang Hann; Wang, Xinquan; Zhang, Linqi
title: Broadly neutralizing and protective nanobodies against diverse sarbecoviruses
date: 2022-04-13
journal: bioRxiv
DOI: 10.1101/2022.04.12.488087
sha: 76ccebbd81b5cd37cc0e6883c19f4c53f4b810d3
doc_id: 931434
cord_uid: b7slt9rg

As SARS-CoV-2 Omicron and other variants of concern continue spreading around the world, development of antibodies and vaccines to confer broad and protective activity is a global priority. Here, we report on the identification of a special group of nanobodies from immunized alpaca with exceptional breadth and potency against diverse sarbecoviruses including SARS-CoV-1, Omicron BA.1, and BA.2. Crystal structure analysis of one representative nanobody, 3-2A2-4, revealed a highly conserved epitope between the cryptic and the outer face of the receptor binding domain (RBD). The epitope is readily accessible regardless of RBD in “up” or “down” conformation and distinctive from the receptor ACE2 binding site. Passive delivery of 3-2A2-4 protected K18-hACE2 mice from infection of authentic SARS-CoV-2 Delta and Omicron. This group of nanobodies and the epitope identified should provide invaluable reference for the development of next generation antibody therapies and vaccines against wide varieties of SARS-CoV-2 infection and beyond.

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to rage 52 around the world, we have witnessed the rapid emergence and turnover of multiple variants of infections among unvaccinated but also break-through infections among the vaccinated 58 individuals 1-4 . Increasing evidence suggests that substantial changes in their antigenic 59 targeted sites on RBD that either overlapped with or proximate to RBM, consistent with their 210 noticeable competition with ACE2 for binding to RBD (Figure 2a) . 211

We then selected one nanobody each from G1 (1-2C7), G2 (Nb70), and G3 (3-2A2-4) to 212 test their neutralizing activity against authentic SARS-CoV-2 such as the wildtype (WT), 213

Alpha, Beta, Delta and Omicron variants, using focus reduction neutralization test (FRNT) . Table S1 ) whereas 3-2A2-4 bound to the SARS-CoV-2 wild type 227 RBD (SARS-CoV-2 WT-RBD) at 2.4 Å resolution (Figure 3d and Table S1 ). The crystal 228 structure of Nb70 was determined in two forms. One was the ternary complex of Nb70 and 229 human antibody P2C-1F11 simultaneously bound to the SARS-CoV-2 WT-RBD at 2.4 Å 230 resolution ( Figure 3b and Table S1 ). The other was the binary complex of Nb70 bound to the 231 SARS-CoV-1 wild type RBD (SARS CoV-1 WT-RBD) at 2.4 Å resolution (Figure 3c and 232 Table S1 ). BA. 2 and WT D614G, with IC50 of 0.032 μg/mL, 0.047 μg/mL, and 0.043 μg/mL respectively. 292

Single substitutions such as G339D, S371L, or S373P had only moderate effect while the triple 293 S371L/S373P/S375F substitutions, like that occurred to Nb70, restored neutralizing activity 294 indistinguishable to that of WT D614G (Figure 4g ). Lastly, sequence alignment of RBD 295 sequences from the multiple sarbecoviruses revealed that epitope residues of 3-2A2-4 and 296

Nb70 were more conserved than that of 1-2C7 (data not shown), providing molecular basis for 297 the broad and potent neutralizing activity of 3-2A2-4 against all sarbecoviruses tested including 298

Omicron BA.1 and BA.2. 299 300

and Delta. We next studied the protective potential of 3-2A2-4 against infection of authentic 302

Omicron and Delta variants in a K18-hACE2 mouse model of SARS-CoV-2 infection, as 303 previously described ( Figure. 5a) 48 . Specifically, the mice were intraperitoneally administered 304 with 3-2A2-4 at a dose of 10 mg/kg body weight 24 hours prior to intranasal challenge with 305 1.7×10 3 plaque-forming units (PFU) of authentic SARS-CoV-2 Omicron or 10 3 PFU of SARS-306

CoV-2 Delta. The animals were then monitored daily throughout the following 14 days for 307 their body weight and survival. Half of the animals were euthanized on day 3 post inoculation 308 to obtain lung tissues for viral load and histopathological analysis. In SARS-CoV-2 Delta challenged groups, untreated animals exhibited faster disease 322 progression and greater severity compared to those in the Omicron challenged group, 323

indicating Delta was more pathogenic than Omicron in this model of SARS-CoV-2 infection, 324 in complete agreement with those recently reported 15,16 . All untreated animals succumbed to 325 diseases by day 6 after challenge, and associated with severe body weight loss (Figure 5e and 326 5f). By contrast, 3-2A2-4-treated group remained fully protected and maintained stable body 327 weights, except for one mouse had to be euthanized on day 6 after infection due to the 328 requirement of experimental protocol when body weight fell below 75% of baseline (Figure 5e The rapid emergence and spread of antigenically distinct SARS-CoV-2 variants such as 340

Omicron BA.1 and BA.2 have resulted in the substantial reduction and loss of activity of many 341 therapeutic antibodies and vaccines 8, 9, [11] [12] [13] . Given the unusual huge number of mutations found 342 in the spike of Omicron BA.1 and BA.2, one of the urgent questions need to be addressed is 343 whether conserved and protective epitopes still exist on the spike trimer that can be targeted 344 for the development of broad and potent antibody therapies and vaccines. Here, we report on 345 the isolation and characterization of a unique group of nanobodies from immunized alpaca. 346

The most outstanding feature of these nanobodies, exemplified by 3-2A2-4, is their exceptional 347 breadth and potency against a highly diverse panel of sarbecoviruses including Omicron BA.1 348 and BA.2, SARS-CoV-1, and the key representatives from bats and pangolins coronaviruses. 349

The IC50 reached as low as 0.042 μg/mL or 0.550 nM against WT D614G and remained 350 relatively stable across the entire panel of the tested viruses. Although neutralization assays 351 differ, this suggests they are amongst the broadest and most potent nanobodies described to 352 date 33-46 . Passive delivery of 3-2A2-4 protected K18-hACE2 mice from infection of two 353 widely spreading SARS-CoV-2 variants Delta and Omicron. Crystal structure analysis together 354 with modeling in the context of spike trimer revealed 3-2A2-4 recognized a highly conserved 355 epitope between the cryptic and outer face of RBD, distinctive from the ACE2 binding site, 356 and readily accessible in both "up" or "down" conformations. Such unique binding pose and 357 specificity provide structural basis for 3-2A2-4 and the other members of the G3 nanobodies 358 in withstanding the mutant residues commonly found in the major variants that compromised 359 many therapeutic antibodies approved for EUA 8,12 . These results clearly indicated that we have 360 identified a broad and protective nanobody that recognized a highly conserved epitope among 361 a diverse panel of sarbecoviruses including Omicron BA.1 and BA.2. The nanobody and the 362 epitope it recognized may serve as an important reference for the development of next 363 generation antibody therapies and vaccines against wide varieties of SARS-CoV-2 infection 364 and beyond. 365

Owing to their nanoscale and extended CDR3, nanobodies are expected to penetrate 366 deeper into the spike trimer and access to hidden epitopes that are less frequently exposed 367 and/or unreachable by conventional antibodies. This is particularly true for the cross-368 neutralizing SARS-CoV-2 and SARS-CoV-1 nanobodies characterized here. Virtually all 369 nanobodies in the G1 and G2 were able to compete with a published nanobody VHH72 known 370 to recognize the hidden epitope accessible only when RBD is in the up conformation 35 . By 371 contrast, the nanobodies in the G3 bound to the epitopes that are readily accessible regardless 372 of up or down conformations of RBD. Interestingly, by screening and characterizing hundreds 373 of monoclonal antibodies from convalescent or vaccinated individuals, a small but convincing 374 number of cross-neutralizing antibodies with similar epitope specificity have also been found 375 39,49-60 . The epitopes recognized by the G1, G2, and G3 nanobodies are therefore not only the 376 viable targets in alpaca but also in humans. In particular, the G1 and G2 nanobodies would fall 377 into the inner face antibodies exemplified by CR3022, H014, S2X259, COVA1-16, CV2-75, 378

and C1c-A3 whereas the G3 nanobodies with the escarpment face antibody 47D11 ( Figure S5 ) 379 61 . Additional cross-neutralizing SARS-CoV-2 and SARS-CoV-1 antibodies targeting to other 380 faces of RBD have also been identified such as those to the cliff face (S2H97 and 6D60), top 381 face (S2X146), and outer face (S309 and BG10-19) ( Figure S5 ). Recently, a human antibody 382 with broad reactivity to human beta-coronaviruses has been isolated that targets the conserved 383 S2 stem-helix, raising the possibility of development of pan-β-CoV therapies and vaccines 62 . 384

More importantly, these cross-neutralizing and pan-β-CoV antibodies can be substantially 385 boosted by mRNA vaccines, particularly in individuals with pre-existing SARS-CoV-1 or 386 SARS-CoV-2 infection 63-65 . Comprehensive characterization of these antibodies will provide 387 us with deeper insights into their ontogeny and potential ways of inducing broader and more 388 effective protection against the circulating and future variants. 389

Taken together, identification of 3-2A2-4 in this work and broadly neutralizing human 390 antibodies elsewhere has revealed the existence of highly conserved and vulnerable sites on 391 the RBD and spike trimer that could potentially be explored to trigger broader and more 392 protective immune responses. This would require preferential exposure of these conserved 393 regions while minimizing the receptor-binding motif that was predominantly recognized 394 during natural infection and vaccination. While to achieve this goal would be expected a huge 395 challenge, recent advances in structure-based vaccine design through understanding of antigen 396 and antibody interaction will undoubtedly provide new conceptual and technological toolbox 397 for this highly anticipated outcome. Identification of 3-2A2-4, as well as other broadly 398 neutralizing antibodies, represent the first but a crucial step for us to achieve the ultimate goal 399 of developing universal vaccine against all SARS-CoV-2 variants including Omicron BA.1 400 and BA. 2, and beyond. into four major groups based on their degrees of competition with ACE2 and control VHH72 464 nanobody with known epitope specificity, measured by surface plasmon resonance (SPR). 465 "++++" indicates >90% competition; "++" 30-60%, and "+" 10-30%. Neutralizing activities of 466 nanobodies against WT D614G were presented by the actual values of 50% inhibitory 467 concentration (IC50) while that against SARS-CoV-2 variants and hACE2-dependent 468 sarbecoviruses were in fold-changes relative to that of WT D614G. IC50 values highlighted in 469 salmon indicate < 0.02 μg/mL; in yellow 0.02-0.1 μg/mL, and in green >0.1 μg/mL. ''-'' 470 indicates increased resistance and ''+'' indicates increased sensitivity to nanobody 471 neutralization. The fold-changes highlighted in red indicate that resistance increased at least 3-472 fold; in blue, sensitivity increased at least threefold; and in white, resistance or sensitivity 473 increased less than 3-fold. BDL indicates that nanobodies at their highest concentration (13.33 474 μg/mL) failed to reach 50% neutralization. Results were calculated from three independent 475 experiments and each performed in technical duplicates. S trimer (residues M1-Q1208) and S2 trimer (residues S686-Q1208) contained proline 531 substitutes at residue 986 and 987, a foldon trimerization motif, and a strep tag at C-terminal. 532

Additional "GSAS" substitution at furin cleavage site (residues 682-685) was also introduced 533 into the S trimer construct to improve overall stability. Both S trimer and S2 trimer were 534 expressed in the FreeStyle 293F cells and purified by Strep-Tactin Sepharose (IBA 535 Lifesciences) followed by gel filtration chromatography (GE Healthcare). The S trimer of 536 SARS-CoV-1, RBD of SARS-CoV-1 and SARS-CoV-2 prototype, and the N-terminal 537 peptidase domain of human ACE2 were expressed using the Bac-to-Bac Baculovirus 538

Expression System (Invitrogen, Carlsbad, CA, USA) and purified by Strep-Tactin Sepharose 539 (IBA Lifesciences) followed by gel filtration chromatography (GE Healthcare), as previously 540

reported 66 . Briefly, the RBD of SARS-CoV-2 wildtype (residues Arg319-Lys529) with an N-541 terminal gp67 signal peptide for secretion and a C-terminal 6×His tag for purification was 542 expressed using Hi5 cells and purified by Ni-NTA resin followed by gel filtration 543 chromatography (GE Healthcare) in HBS buffer (10 mM HEPES, pH 7.2, 150 mM NaCl). The 544 RBD of SARS-CoV-1 (residues Arg306-Leu515) and N-terminal peptidase domain of human 545 ACE2 (residues S19-D615) were expressed and purified by the same protocol as used for the 546 RBD of SARS-CoV-2 wildtype (see above). The SARS-CoV-2 NTD protein was purchased 547 from SinoBiological (40591-V49H). immunization, blood samples were collected to isolate peripheral blood lymphocytes and 558 plasma. Total RNA was extracted from the peripheral blood lymphocytes and used as the 559 template for the first strand cDNA synthesis, using oligo dT as a primer. VHH sequences were 560 amplified by PCR, cloned into a yeast surface display vector pYD1, and introduced into the 561 electrocompetent EBY100 cells. The yeast library was first grown in SDCAA media at 30 °C 562 for 48 h. At the exponential growth phase, the yeast library was transferred to SGCAA media 563 Facility. Diffraction data were processed using the HKL3000 software (PMID:16855301) and 716 the data-processing statistics are listed in Table S1 . Q1  G400  Q1  G413  Q1  L378  S29  D364  T402  T28  D427  L31  Y369  V367  T28  D414  D428  P384  L31  L335  D415  R31  Y380  R57  A372  V362  R31  Y367  G381  R100  T376  A363  G368  D428  F377  D364  D415  F429  L378  P527  F416  T430  P101  Y369  V33  L335  M417  Y32  Y380  F374  L53  T333  Y32  Y367  P412  S375  N334  P399  E52  S383  F377  L335  E52  S370  W53  G381  S102  Y369  V362  W53  V369  V382  S371  D54  T333  G368  S383  A372  E98  L335  S370  G100  C379  S373  N99  V367  G100  C366  Y380  F374  G100  A363  Y367  N101  L378  F377  D364  N101  L365  C379  A103  Y369  V367  C366  G381  N370  G101  L335  G368  V382  S371  C336  V369  P384  H104  N370  F338  A371  Q102  F377  S371  G339  Q102  F364  L378  A372  F102  F338  L365  P384  Y105  S371  G339  A371  Y103  Y369  A372  F342  Y103  Y356  F377  F374  N343  F364  P384  S375  D364  A371  Y104  S371  Y109  V503  Y365   T372   A372  T111  V503  L368  Y104  T359  F374  G504  F103  F342  F361  Y114  R408  Q112  S375  N343  N112  R395  D115  L378  Y508  V367  E113  R395  Y380  D114  L378  S371  Y114  R395  R408  F374  D115  L365  A411  Y104  G339  Y367  Q414  N343  R395  F116  P412  A398  G413  Q401  Q414  F116 P399 W117 R408 G400 Q401

Breakthrough infections with SARS-CoV-2 782 omicron despite mRNA vaccine booster dose

Effect of Covid-19 Vaccination on Transmission of Alpha and Delta 785

Genomic characterization and epidemiology of an emerging SARS-787

CoV-2 variant in Delhi

Evidence for increased breakthrough rates of SARS-CoV-2 variants of 789 concern in BNT162b2-mRNA-vaccinated individuals

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. 792

Analysis of SARS-CoV-2 variant mutations reveals neutralization 794 escape mechanisms and the ability to use ACE2 receptors from additional species

Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced 797 immunity

Striking antibody evasion manifested by the Omicron variant of SARS-799

Variant Neutralization in Serum from Vaccinated and Convalescent Persons

mRNA-based COVID-19 vaccine boosters induce 804 neutralizing immunity against SARS-CoV-2 Omicron variant

Activity of convalescent and vaccine serum against SARS-CoV-2

Omicron escapes the majority of existing SARS-CoV-2 neutralizing 809 antibodies

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 811 variant by post-immunisation serum

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron 814 antigenic shift

SARS-CoV-2 Omicron virus causes attenuated disease in mice 816 and hamsters

Attenuated replication and pathogenicity of SARS-CoV-2 B

SARS-CoV-2 Omicron variant replication in human bronchus and 820 lung ex vivo

Relative instantaneous reproduction number of 822

CoV-2 variant with respect to the Delta variant in Denmark

BNT162b vaccines protect rhesus macaques from SARS-CoV-2. 825

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 827 pneumonia in rhesus macaques